Article
Things to Do in Austin
February 1, 2023
Austin, Texas is not only the Live Music Capital of the World but also home to SHM Converge 2023, March 26-29 at the Austin Convention Center. Plan your conference experience and take advantage of...
Article
The Hospitalist’s Editorial Board Members’ Must-attend SHM Converge 2023 Sessions
February 1, 2023
SHM Converge 2023 offers world-class education for hospitalists, led by award-winning faculty. Engage with your global hospitalist community March 26-29, 2023, in Austin, Texas. With more than 150...
Article
SHM Converge 2023—Reconnect Again!
February 1, 2023
Get ready for an exciting, dynamic, inspiring event in the Lone Star State’s capital at SHM Converge 2023! We’re truly excited to see you all again, following our grand collective reconnection...
News
Epilepsy linked to 1.5-fold higher COVID-19 mortality in hospital
December 14, 2021
Findings suggest higher risk although researchers haven’t adjusted findings for confounders yet.
![1]()
News
SGLT2 inhibitor use tied to fewer atrial arrhythmias
December 2, 2021
A prospective study of nearly 14,000 patients who received an implantable cardiac device suggests that SGLT2-inhibitor treatment cuts atrial arrhythmias.
News
Advanced CKD doesn’t derail empagliflozin in EMPEROR-preserved
November 19, 2021
Study shows empagliflozin led to a consistent, significant relative risk reduction compared with placebo in the primary endpoint.
![1]()
News
Empagliflozin a winner in challenging arena of stabilized acute HF
November 19, 2021
Early in-hospital initiation of SGLT2 inhibitors “should be considered the new standard of care” in most patients with heart failure regardless of their ejection fraction, says an expert observer.
![1]()
News
EMPEROR-Preserved findings confirmed in ‘true’ HFpEF patients
November 17, 2021
A landmark trial proved empagliflozin’s efficacy in HFpEF, but many patients had “moderately reduced” EFs. The findings hold up even without them.
![1]()
News
Ticagrelor reversal agent achieves quick hemostasis: REVERSE-IT
November 17, 2021
The monoclonal antibody bentracimab, which can rapidly reverse ticagrelor, was found effective and safe in an FDA-requested interim analysis of a phase 3 trial.
![1]()
News
EHRs have no impact on inpatient heart failure clinical choices or outcomes
November 15, 2021
Relative to usual care, prognostic information at the bedside provided no advantage for heart failure care.
